ImpediMed Shares soar on NCCN Guidelines update
- Impedimed (IPD) shares soar on Monday after the US National Comprehensive Cancer Network (NCCN) recommends regular screenings with bioimpedance spectroscopy
- This marks the first time the NCCN’s Clinical Practice Guidelines in Oncology for Survivorship has included bioimpedance spectroscopy
- The NCCN guidelines are the globally-recognised standard for clinical direction and policy in cancer care to improve patient outcomes
- The company currently has the only FDA-cleared bioimpedance spectroscopy technology for the assessment of lymphoedema
- The company shares skyrocket 55.93 per cent, trading at 9.2 cents at 1:45 pm AEDT
